Cardiome Pharma Corp. launched the Xydalba skin treatment ahead of schedule in Germany.
The drug is approved by the European Medicines Agency to treat adults with acute bacterial skin and skin structure infections, or ABSSSI. It has already been launched in the U.K.
The drug is planned for further launch in other European countries. The German ABSSSI hospital market is valued at $123 million, according to Datamonitor.